U266 Cells
545,10 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | The U266 cell line, also known as U-266, is a human multiple myeloma cell line that was established from the peripheral blood of a 53-year-old man with IgE myeloma. This cell line is characterized by the secretion of both light and heavy immunoglobulin chains, predominantly lambda light chains and IgE heavy chains. The U266 cell line exhibits typical B lymphocyte markers and has been used extensively in the study of myeloma biology, particularly in understanding the pathophysiological mechanisms of plasma cell malignancies and the immune response. U266 cells are valuable for their role in drug discovery and development, providing a robust model for evaluating the efficacy of anti-myeloma agents. They are also utilized in the study of myeloma cell interactions with the bone marrow microenvironment, which is crucial for understanding myeloma progression and resistance to therapy. Genetic studies have revealed several chromosomal abnormalities in U266 cells, which contribute to their malignant phenotype and resistance to apoptosis. This cell line has been instrumental in the advancement of molecular targeted therapies in multiple myeloma. |
|---|---|
| Organisme | Human |
| Tissu | Plasma cell |
| Maladie | Multiple Myeloma |
| Synonymes | U266B1, U266-B1, U266 B1, U-266, U 266, U266S, U266BL, U266 |
Caractéristiques
| Âge | 53 years |
|---|---|
| Genre | Male |
| Propriétés de croissance | Suspension |
Données réglementaires
| Référence | U266 (Cytion catalog number 300259) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_0566 |
Données biomoléculaires
Manipulation
| Milieu de culture | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suppléments | Supplement the medium with 10% heat-inactivated FBS |
| Repiquage | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Densité de semis | 5 x 105 cells/mL |
| Rétablissement après le dégel | After thawing allow the cells to recover from the freezing process for at least 24 hours. |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificat d'analyse (CoA)
| Numéro de lot | Type de certificat | Date | Numéro de catalogue |
|---|---|---|---|
| 300259-221 | Certificat d'analyse | 23. May. 2025 | 300259 |
| 300259-250324 | Certificat d'analyse | 23. May. 2025 | 300259 |
| 300259-280225 | Certificat d'analyse | 23. May. 2025 | 300259 |